Quantcast
Last updated on April 21, 2014 at 9:29 EDT

Latest ScinoPharm Stories

2012-07-18 18:20:40

TAINAN, Taiwan, July 18, 2012 /PRNewswire-Asia/ -- ScinoPharm (TWSE:1789) announced today that its Tainan, Taiwan Facility will provide commercial manufacturing of topiramate active pharmaceutical ingredient ("API") for VIVUS' Qsymia(TM), a new drug for the treatment of obesity approved by the United States Food and Drug Administration on July 17, 2012. Qsymia(TM) is the first FDA-approved once daily combination treatment for chronic weight management in adults who are obese or...

2012-06-28 22:20:44

TAINAN, Taiwan, June 29, 2012 /PRNewswire-Asia/ -- ScinoPharm (TWSE:1789) announced today that it will invest NT$1.13 billion (approximately US$37.6 million) in the construction of a high potency cytotoxic injectable plant suitable for production of oncological injectable products on the company's premise at the Tainan Science Park. ScinoPharm, a global leader in supplying oncological APIs for injectable products, currently has the most number of oncological APIs for the generic industry....

2011-02-08 01:00:00

TAINAN, Taiwan, Feb. 8, 2011 /PRNewswire-Asia/ -- ScinoPharm, a leading active pharmaceutical ingredient (API) and contract research and manufacturing (CRAM) service provider to the global pharmaceutical and biotechnology industry, will provide commercial manufacturing service of vilazodone hydrochloride active pharmaceutical ingredient (API) for Clinical Data, Inc.'s Viibryd(TM), a new drug entity recently approved by the United States Food and Drug Administration. Viibryd is a novel...

2010-03-25 00:00:00

TAIWAN, March 25 /PRNewswire-Asia/ -- ScinoPharm, an active pharmaceutical ingredient (API) specialist, today announced audited record results for its fiscal year 2009. The company posted NT$3.791 billion in revenue, an increase of 20.54% over 2008. The company posted after-tax profit of NT $1.041 billion, an increase of approximately 19.37% over 2008. The increase was driven by the continued strong sales of its anti-cancer and other therapeutic treatments products, as well as...

2009-11-19 15:00:00

TAINAN, Taiwan, Nov. 19 /PRNewswire-Asia/ -- ScinoPharm, a leading global supplier of active pharmaceutical ingredients (APIs), announced that its Tainan facility has received the Potent Compound Safety Certification from SafeBridge(R) Consultants, Inc. The Certification confirms ScinoPharm's competency and proficiency in the safe handling of potent active pharmaceutical ingredients (APIs), and applies to specific laboratories and production areas used for the manufacturing and handling...

2009-11-05 06:40:00

TAINAN, Taiwan, Nov. 5 /PRNewswire-Asia/ -- ScinoPharm, a leading global supplier of active pharmaceutical ingredients (APIs), has commenced construction of a new plant on a 66670 square meter site. The facilities, located in Changshu, Jiangsu province in China, will include a R&D centre and production plants fully compliant with U.S. and international GMP standards. The Changshu plant, slated to be fully operational by 2011, will be used for the production of GMP grade...